Loading...
•
Dec 31, 2021
10X Genomics Q4 2021 Earnings Report
10x Genomics reported Q4 2021 earnings with a 28% revenue increase and provided 2022 outlook.
Key Takeaways
10x Genomics reported a 28% increase in revenue for Q4 2021, reaching $143.5 million. The company's operating loss was $15.8 million, and net loss was $18.4 million. They also provided full year 2022 revenue guidance of $600 million to $630 million.
Revenue for Q4 2021 was $143.5 million, a 28% increase year-over-year.
Gross margin for Q4 2021 was 81%, compared to 83% in the prior year period.
Operating loss for Q4 2021 was $15.8 million, a significant improvement from the $409.6 million loss in the prior year period.
Net loss for Q4 2021 was $18.4 million, compared to a net loss of $415.6 million in the prior year period.
Forward Guidance
10x Genomics expects full year 2022 revenue to be in the range of $600 million to $630 million, representing 22% to 28% growth over full year 2021 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...